Speakers 2023

Speaker line-up of 2023

Amir Nakar

Scientific Affairs Specialist, MeMed

Anand Anandkumar

Chief Executive Officer, Bugworks Research Inc.

Anders Karlén

Professor in Computer-Aided Drug Design

Athanasios Typas

Group Leader & Senior Scientist, European Molecular Biology Laboratory

Bernhard Kerscher

Head of Laboratory & Preclinical Assessor, Paul-Ehrlich-Institut - German Federal Institute for Vaccines and Biomedicines

Betsy Wonderly Trainor

Alliance Director Diagnostics, CARB-X

Bita Sehat

Senior Investment Director, Trill Impact

Chantal Morel

Health economist in anti-microbial resistance, KPM Center for Public Management, University of Bern

Christoph Dehio

Full Professor of Molecular Microbiology, Director of National Centre of Competence in Research (NCCR) “AntiResist”

Deborah O’Neil

CEO, NovaBiotics Ltd & Board Member, BEAM Alliance

Dominic O’Neil

Director Microbiome Product Development, QIAGEN GmbH

Douglas Häggström

Manager INCATE, University of Basel

Ed Buurman

Alliance Director CARB-X

Giancarlo Biagini

Head of the Department of Tropical Disease Biology, Liverpool School of Tropical Medicine

Glenn E. Dale

Chief Development Officer, BioVersys AG

Hasan Jafri

Chief Medical Officer, Aridis Pharmaceuticals Inc.

Jan Poolman

Vice-President, Head Bacterial Vaccine Discovery and Early Development, Janssen Vaccines & Prevention B.V.

John Alter

Head of External Affairs, AMR Action Fund

John Rex

Chief Medical Officer, F2G Ltd. & Operating Partner, Advent Life Sciences

Kevin Outterson

Austin B Fletcher Professor, Boston University, and Executive Director & Principal Investigator, CARB-X

Marc Gitzinger

CEO, BioVersys AG & Vice President, BEAM Alliance

Maria Uria-Nickelsen

Alliance Director, CARB-X

Mark Jones, PhD PMP

Head of Development, Basilea Pharmaceutica International Ltd | BEAM Alliance - Board Member | Swiss Round Table for Antibiotics - Board Member

Marlieke De Kraker

Senior epidemiologist, Geneva University Hospitals and Faculty of Medicine

Martin Heidecker

Chief Investment Officer, AMR Action Fund
Martin J. Boeree

Martin J. Boeree

Professor in clinical tuberculosis, Radboud universitair medisch centrum

Morgane Vanbiervliet

Manager, Market Intelligence & Business Development, Infectious Diseases, Debiopharm International SA

Peter Jackson

Executive director, Infex Therapeutics

Rachel Silverman Bonnifield

Senior Fellow, Center for Global Development

Rakel Arrazuria

Researcher, Microbiology Division, Paul-Ehrlich-Institut - German Federal Institute for Vaccines and Biomedicines

Ralf Sudbrak

Interim Secretariat Lead, Global AMR R&D Hub

Remko van Leeuwen

Chief Executive Officer, Madam Therapeutics

Shampa Das

Deputy Head of Department of Pharmacology and Therapeutics, University of Liverpool

Su Chiang

Senior Alliance Manager, CARB-X, Boston University

Taslimarif Saiyed

Director and CEO, Centre for Cellular and Molecular Platforms

Urs Jenal

Professor of Infection Biology, University of Basel & Co-director of NCCR AntiResist

Wolfgang Philipp

Acting Deputy Head HERA, European Commission

Yann Ferrisse

Director, Business Development & Partner Engagement, GARDP Foundation

Zemer Gitai

EG Conklin Professor, Department of Molecular Biology, Princeton University and Founder, ArrePath Inc.

More speaker profiles will be published soon.